A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2028-01-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether the addition of selexipag to standard of
care treatment delays disease progression in children with Pulmonary Arterial Hypertension
(PAH) in comparison to placebo.